Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Pharmacokinetics Services Market Size, Share and Trends Report, 2026-2033 | Predictive PK/PD Models Drive 7.7% CAGR and a USD 3.6 Billion Opportunity

globenewswire.com
CRL Charles River Laboratories is mentioned as a market participant in the pharmacokinetics services market, which is projected to grow. The article does not provide specific sentiment towards the company itself. EVTC Evotec is listed as a key market participant in the growing pharmacokinetics services market. The article does not offer specific positive or negative sentiment about Evotec's performance or prospects.

Global Pharmacokinetics Services Market Size, Share and Trends Report, 2026-2033 | Predictive PK/PD Models Drive 7.7% CAGR and a USD 3.6 Billion Opportunity Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Pharmacokinetics Services Market Size, Share & Trends Analysis Report 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global pharmacokinetics services market was valued at USD 2.0 billion in 2025 and is projected to increase from USD 2.1 billion in 2026 to USD 3.6 billion by 2033. The market is expected to expand at a CAGR of 7.7% from 2026 to 2033. North America led the global market in 2025, accounting for 37.0% of total revenue.

Poor pharmacokinetics (PK) remains a major contributor to drug attrition, encouraging pharmaceutical and biotechnology companies to incorporate PK evaluations of novel molecular entities throughout drug discovery and clinical development. The integration of predictive preclinical pharmacokinetics/ pharmacodynamics (PK/PD) models into clinical trial programs supports the early identification of development risks and enables timely modifications to dosing, study design, and broader development strategies.

Growing recognition of pharmacokinetic and toxicological studies among physicians, surgeons, researchers, and patients is supporting demand for specialized pharmacokinetics services. These studies play an important role in establishing human equivalent doses, no observed effect levels, therapeutic exposure, and safety parameters. Government agencies and regulatory bodies are also pursuing greater standardization of pharmacokinetic protocols as clinical data requirements continue to evolve.

Regulatory expectations for clinical pharmacokinetic data increasingly emphasize the safety implications of drug candidates. PK studies help determine initial dosing levels, therapeutic effects, and potential adverse effects. PK/PD analysis also supports the progression of candidates from preclinical research into rapid and efficient in-man studies. Human in vivo and in vitro models are widely used to evaluate pharmacokinetic variability during clinical development.

Phase I clinical trials provide the first opportunity to characterize a drug candidate's pharmacokinetic profile in humans. Conducted in healthy volunteers or, in areas such as oncology, in patients, these trials help establish acceptable and safe doses for subsequent clinical trial stages. The growing importance of these evaluations is expected to sustain demand for contract pharmacokinetics services across the pharmaceutical industry.

Market participants are broadening their service portfolios to support multiple phases of pharmaceutical development and strengthen their competitive positions. Pharmacokinetics services are also becoming more closely integrated with toxicology, clinical pharmacology, and commercialization planning. However, limitations associated with in vitro PK studies, including the inability of existing experiments and protocols to predict the complete interaction between a target and a drug candidate, may constrain market growth.

Report Scope and Segmentation

The report provides global, regional, and country-level revenue analysis, market forecasts, competitive intelligence, and assessments of emerging pharmacokinetics services market trends. Coverage includes opportunities across drug type, application, end use, and region from 2021 to 2033.

Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)

Application Outlook (Revenue, USD Billion, 2021 - 2033)

End Use Outlook (Revenue, USD Billion, 2021 - 2033)

Regional Outlook (Revenue, USD Billion, 2021 - 2033)

Strategic Value of the Report

The report equips pharmaceutical companies, biotechnology organizations, research institutions, investors, and other stakeholders with market intelligence for opportunity identification, competitive benchmarking, expansion planning, and long-term decision-making in the global pharmacokinetics services market.

Key Topics Covered:

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.1.1. Drug Type

1.1.2. Application

1.1.3. End use

1.1.4. Regional scope

1.1.5. Estimates and forecast timeline

1.2. Research Methodology

1.3. Information Procurement

1.3.1. Purchased database

1.3.2. The internal database

1.3.3. Secondary sources

1.3.4. Primary research

1.3.5. Details of primary research

1.4. Information or Data Analysis

1.4.1. Data analysis models

1.5. Market Formulation & Validation

1.6. Model Details

1.7. List of Secondary Sources

1.8. List of Primary Sources

1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Drug Type outlook

2.2.2. Application outlook

2.2.3. End use outlook

2.2.4. Regional outlook

2.3. Competitive Insights

Chapter 3. Pharmacokinetic Services Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Market Dynamics

3.3.1. Market driver analysis

3.3.2. Market restraint analysis

3.4. Pharmacokinetic Services Market Analysis Tools

3.4.1. Industry Analysis - Porter's

3.4.1.1. Supplier power

3.4.1.2. Buyer power

3.4.1.3. Substitution threat

3.4.1.4. Threat of new entrant

3.4.1.5. Competitive rivalry

3.4.2. PESTEL Analysis

3.4.2.1. Political landscape

3.4.2.2. Technological landscape

3.4.2.3. Economic landscape

Chapter 4. Pharmacokinetic Services Market: Drug Type Estimates & Trend Analysis

4.1. Pharmacokinetic Services Market, Key Takeaways

4.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030

4.3. Small Molecule

4.3.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)

4.4. Large Molecules (Biopharmaceuticals)

4.4.1. Large molecule (biopharmaceuticals) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Pharmacokinetic Services Market: Application Estimates & Trend Analysis

5.1. Pharmacokinetic Services Market, Key Takeaways

5.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030

5.3. Small and Medium Enterprise

5.3.1. Small and medium enterprise market estimates and forecasts, 2018 to 2030 (USD Million)

5.4. Large Enterprise

5.4.1. Large enterprise market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmacokinetic Services Market: End Use Estimates & Trend Analysis

6.1. Pharmacokinetic Services Market, Key Takeaways

6.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030

6.3. Biotechnology & Pharmaceutical Companies

6.3.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)

6.4. Academic & Government Research Institutes

6.4.1. Academic & government research institutes market estimates and forecasts, 2018 to 2030 (USD Million)

6.5. Others

6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Pharmacokinetic Services Market: Regional Estimates & Trend Analysis

7.1. Regional Outlook

7.2. Pharmacokinetic Services Market by Region: Key Takeaways

7.3. North America

7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.3.2. U.S.

7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.3.3. Canada

7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4. Europe

7.4.1. UK

7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.2. Germany

7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.3. France

7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.4. Italy

7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.5. Spain

7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.6. Denmark

7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.7. Sweden

7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.4.8. Norway

7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5. Asia Pacific

7.5.1. Japan

7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5.2. China

7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5.3. India

7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5.4. Australia

7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5.5. Thailand

7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.5.6. South Korea

7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.6. Latin America

7.6.1. Brazil

7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.6.2. Mexico

7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.6.3. Argentina

7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.7. MEA

7.7.1. South Africa

7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.7.2. Saudi Arabia

7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.7.3. UAE

7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

7.7.4. Kuwait

7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, Key Market Participants

8.2. Market Participant Categorization

8.2.1. Evotec AG

8.2.1.1. Company overview

8.2.1.2. Financial performance

8.2.1.3. Product benchmarking

8.2.1.4. Strategic initiatives

8.2.2. Certara, L.P.

8.2.2.1. Company overview

8.2.2.2. Financial performance

8.2.2.3. Product benchmarking

8.2.2.4. Strategic initiatives

8.2.3. Pacific BioLabs

8.2.3.1. Company overview

8.2.3.2. Financial performance

8.2.3.3. Product benchmarking

8.2.3.4. Strategic initiatives

8.2.4. GVK Biosciences Private Limited

8.2.4.1. Company overview

8.2.4.2. Financial performance

8.2.4.3. Product benchmarking

8.2.4.4. Strategic initiatives

8.2.5. Shanghai Medicilon Inc.

8.2.5.1. Company overview

8.2.5.2. Financial performance

8.2.5.3. Product benchmarking

8.2.5.4. Strategic initiatives

8.2.6. Pharmaceutical Product Development, LLC

8.2.6.1. Company overview

8.2.6.2. Financial performance

8.2.6.3. Product benchmarking

8.2.6.4. Strategic initiatives

8.2.7. Charles River Laboratories International, Inc.

8.2.7.1. Company overview

8.2.7.2. Financial performance

8.2.7.3. Product benchmarking

8.2.7.4. Strategic initiatives

8.2.8. PAREXEL International Corporation

8.2.8.1. Company overview

8.2.8.2. Financial performance

8.2.8.3. Product benchmarking

8.2.8.4. Strategic initiatives

8.2.9. Eurofins Scientific, Inc.

8.2.9.1. Company overview

8.2.9.2. Financial performance

8.2.9.3. Product benchmarking

8.2.9.4. Strategic initiatives

8.2.10. Frontage Labs

8.2.10.1. Company overview

8.2.10.2. Financial performance

8.2.10.3. Product benchmarking

8.2.10.4. Strategic initiatives

8.2.11. SGS SA

8.2.11.1. Company overview

8.2.11.2. Financial performance

8.2.11.3. Product benchmarking

8.2.11.4. Strategic initiatives

8.2.12. LGC Limited

8.2.12.1. Company overview

8.2.12.2. Financial performance

8.2.12.3. Product benchmarking

8.2.12.4. Strategic initiatives

8.2.13. Creative Bioarray

8.2.13.1. Company overview

8.2.13.2. Financial performance

8.2.13.3. Product benchmarking

8.2.13.4. Strategic initiatives

List of Tables [90]

List of Figures [59]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/ngyi55

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.